WallStSmart
TARS

Tarsus Pharmaceuticals Inc

NASDAQ: TARS · HEALTHCARE · BIOTECHNOLOGY

$60.67
-2.29% today

Updated 2026-04-29

Market cap
$2.61B
P/E ratio
—
P/S ratio
5.78x
EPS (TTM)
$-1.59
Dividend yield
—
52W range
$39 – $85
Volume
0.6M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Tarsus Pharmaceuticals Inc (TARS) Financial statements

SEC filings — annual and quarterly data.

Income statementBalance sheetCash flowProfitability

Income statement — annual

Item20182019202020212022202320242025
Revenue$0.00$0.00$33.43M$57.03M$25.82M$17.45M$182.95M$451.36M
Revenue growth (YoY)———+70.6%-54.7%-32.4%+948.6%+146.7%
Cost of revenue$1000.00$74000.00$246000.00$2.08M$955000.00$1.59M$12.83M$30.68M
Gross profit$-1000.00$-74000.00$-246000.00$54.95M$24.86M$15.85M$170.13M$420.68M
Gross margin——-0.7%96.4%96.3%90.9%93.0%93.2%
R&D$901000.00$3.16M$18.83M$41.71M$42.62M$50.31M$53.39M$64.32M
SG&A$449000.00$1.14M$8.17M$25.40M$44.95M$80.33M$237.31M$427.32M
Operating income$-1.35M$-4.30M$-26.98M$-12.16M$-62.71M$-143.16M$-120.57M$-70.97M
Operating margin——-80.7%-21.3%-242.9%-820.5%-65.9%-15.7%
EBITDA$-1.32M$-4.55M$-26.56M$-13.46M$-59.70M$-131.67M$-106.48M$-53.61M
EBITDA margin——-79.5%-23.6%-231.3%-754.7%-58.2%-11.9%
EBIT$-1.32M$-4.63M$-26.81M$-13.77M$-60.03M$-132.55M$-107.70M$-55.42M
Interest expense$0.00$40000.00$188000.00$2.88M$2.06M$3.23M$7.45M$8.94M
Income tax————————
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-1.32M$-4.67M$-26.81M$-13.83M$-62.09M$-135.89M$-115.55M$-66.42M
Net income growth (YoY)—-254.1%-474.1%+48.4%-349.1%-118.9%+15.0%+42.5%
Profit margin——-80.2%-24.2%-240.5%-778.9%-63.2%-14.7%